PRO-KIDNEY: Prone Position and Renal Resistive Index

Sponsor
University Hospital, Grenoble (Other)
Overall Status
Unknown status
CT.gov ID
NCT04286490
Collaborator
French Society for Intensive Care (Other), Act For Chronic Diseases (Other)
29
1
24

Study Details

Study Description

Brief Summary

Patients suffering from Acute Respiratory Distress Syndrome (ARDS) with a prone position (PP) indication will benefit from measurements of radiological and biological kidney injury markers, intra-abdominal pressure (IAP) and ventilatory mechanics in supine position (baseline IAP), after 2 hours in PP at the current IAP value, thirty minutes after patients' abdomen suspension in order to resume baseline IAP and after patients' are turned back to supine position.

Condition or Disease Intervention/Treatment Phase
  • Other: Prone position
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
29 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Other
Official Title:
Effect of Prone Position on Renal Resistive Index Among Patients With Acute Respiratory Distress Syndrome. The Role of Intra-abdominal Pressure
Anticipated Study Start Date :
Jun 1, 2020
Anticipated Primary Completion Date :
Jun 1, 2022
Anticipated Study Completion Date :
Jun 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Prone position

Other: Prone position
Abdomen suspension in prone position

Outcome Measures

Primary Outcome Measures

  1. change in renal resistive index (RRI) [At inclusion (in supine position), two hours after prone positioning, 30-minutes after the abdomen suspension maneuver]

    RRI measurement will be performed on a right kidney arcuate/interlobar artery, with a high frequency Doppler probe. Three to five consecutive measures will be obtained then RRI computed according to the formula: (peak systolic velocity - end diastolic velocity)/peak systolic velocity).

Secondary Outcome Measures

  1. change in renal medullary oxygen tension [At inclusion (in supine position), two hours after prone positioning, 30-minutes after the abdomen suspension maneuver]

    urinary oxygen tension (uPO₂) will be measured via a fiber-optic luminescence optode inserted through the bladder catheter lumen

  2. change in cell-cycle arrest biomarkers [At inclusion (in supine position), two hours after prone positioning, 30-minutes after the abdomen suspension maneuver]

    Tissue inhibitor of metalloproteinases 2 and Insulin-like growth factor-binding protein 7 concentrations product ([TIMP2] · [IGFBP7]) will be measured with a sandwich immunoassay technique

  3. ventilatory mechanics: transpulmonary pressure [At inclusion (in supine position), two hours after prone positioning, 30-minutes after the abdomen suspension maneuver]

    transpulmonary pressure will be measured at the end of inspiration and expiration and continuously recorded on a datalogger

  4. ventilatory mechanics: driving pressure [At inclusion (in supine position), two hours after prone positioning, 30-minutes after the abdomen suspension maneuver]

    driving pressure will be measured at the end of inspiration and expiration and continuously recorded on a datalogger

  5. ventilatory mechanics: elastance [At inclusion (in supine position), two hours after prone positioning, 30-minutes after the abdomen suspension maneuver]

    elastance will be measured at the end of inspiration and expiration and continuously recorded on a datalogger

  6. haematosis [At inclusion (in supine position), two hours after prone positioning, 30-minutes after the abdomen suspension maneuver]

    arterial oxygen tension (PaO2) and arterial dioxide carbon tension (PaC02)

  7. Intra abdominal pressure [At inclusion (in supine position), two hours after prone positioning, 30-minutes after the abdomen suspension maneuver and two hours after patients are back in supine position]

    Intra abdominal pressure will be measured thanks to a dedicated nasogastric tube with two balloons (gastric pressure)

  8. Persisting effect of IAP increase in prone position when patients are back in supine position on renal resistive index [Two hours after patients are back in supine position]

    RRI measurement will be performed on a right kidney arcuate/interlobar artery, with a high frequency Doppler probe. Three to five consecutive measures will be obtained then RRI computed according to the formula: (peak systolic velocity - end diastolic velocity)/peak systolic velocity).

  9. Persisting effect of IAP increase in prone position when patients are back in supine position on urinary PO2 [Two hours after patients are back in supine position]

    urinary oxygen tension (uPO₂) will be measured via a fiber-optic luminescence optode inserted through the bladder catheter lumen

  10. Persisting effect of IAP increase in prone position when patients are back in supine position on cell-cycle arrest biomarkers [Two hours after patients are back in supine position]

    Tissue inhibitor of metalloproteinases 2 and Insulin-like growth factor-binding protein 7 concentrations product ([TIMP2] · [IGFBP7]) will be measured with a sandwich immunoassay technique

  11. Persisting effect of IAP increase in prone position when patients are back in supine position on ventilatory mechanics: transpulmonary pressure [Two hours after patients are back in supine position]

    transpulmonary pressure will be measured at the end of inspiration and expiration and continuously recorded on a datalogger

  12. Persisting effect of IAP increase in prone position when patients are back in supine position on ventilatory mechanics: driving pressure [Two hours after patients are back in supine position]

    driving pressure will be measured at the end of inspiration and expiration and continuously recorded on a datalogger

  13. Persisting effect of IAP increase in prone position when patients are back in supine position on ventilatory mechanics: elastance [Two hours after patients are back in supine position]

    elastance will be measured at the end of inspiration and expiration and continuously recorded on a datalogger

  14. Persisting effect of IAP increase in prone position when patients are back in supine position on haematosis [Two hours after patients are back in supine position]

    arterial oxygen tension (PaO2) and arterial dioxide carbon tension (PaC02)

  15. Acute kidney injury [within 48 hours following prone position]

    According to creatinine or diuresis criteria of Kidney Disease: Improving Global Outcomes (K-DIGO) classification

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • ARDS patients according to Berlin criteria, intubated, mechanically ventilated since at least 24 hours,

  • with PaO₂/FiO₂ < 150 mmHg,

  • neuromuscular blockade

  • with an indication of PP done by the physician in charge

  • possibility to differ PP for one hour

  • patients should be hemodynamically stable since at least 4 hours

Exclusion Criteria:
  • Pregnant or breast-feeding women

  • legal protection, no social security affiliation

  • PP contra-indication

  • nasogastric tube contra-indication

  • extra corporeal membrane oxygenation

  • acute kidney injury at inclusion according to K-DIO criteria, chronic kidney disease defined as an estimated glomerualr filtration rate less than 30 ml/min/1.73m², kidney transplantation, renal artery stenosis, solitary kidney, albuminuria > 1.25 mg/ml

  • cardiac arrhythmia

  • obesity

  • advanced cirrhosis

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • University Hospital, Grenoble
  • French Society for Intensive Care
  • Act For Chronic Diseases

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University Hospital, Grenoble
ClinicalTrials.gov Identifier:
NCT04286490
Other Study ID Numbers:
  • 38RC19.265
First Posted:
Feb 27, 2020
Last Update Posted:
May 12, 2020
Last Verified:
May 1, 2020
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 12, 2020